Stockreport

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first doseRepresents first study to report time-averag [Read more]